Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 39,800 shares, a growth of 22.1% from the January 31st total of 32,600 shares. Based on an average daily volume of 14,100 shares, the short-interest ratio is currently 2.8 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Trading of Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new stake in Prenetics Global Limited (NASDAQ:PRE) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global as of its most recent SEC filing. 25.01% of the stock is owned by institutional investors and hedge funds.

Prenetics Global Stock Performance

Shares of PRE opened at $4.81 on Thursday. The stock has a 50 day moving average price of $5.51 and a two-hundred day moving average price of $5.01. The firm has a market capitalization of $58.65 million, a P/E ratio of -1.20 and a beta of -0.31. Prenetics Global has a 52 week low of $2.85 and a 52 week high of $7.84.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $9.00 price objective on shares of Prenetics Global in a report on Thursday, January 16th.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.